Researchers
Roper, Randall J PHD
Indiana University - Purdue University Indianapolis
INCLUDE Grants
Modifiers of Down Syndrome Co-occurring Phenotypes
Grant Number
R01HD118475
NIH Institute
NICHD
Mechanism
R01
NARRATIVE
The proposed research is relevant to public health because it will create new mouse models that are more like
the human Down syndrome condition to identify modifier genes and molecules contributing to the incidence
and severity of DS skeletal and cognitive phenotypes, as well as differences between sexes in these
phenotypes. This research will provide a foundation to change how the gene-phenotype relationships are
deduced in Down syndrome and other syndromic disorders, propose relevant treatments, and ensure that that
all children have the chance to achieve their full potential free from disease or disability.
Development and treatment of skeletal deficits in a Down syndrome mouse model
Grant Number
R15HD090603
NIH Institute
NICHD
Mechanism
R15
The proposed research is relevant to public health because it will identify genetic, cellular and molecular bases of skeletal phenotypes related to Down syndrome, as well as differences between the sexes in bone development related to Trisomy 21. The projects outlined in this proposal will be done with a team primarily composed of undergraduate students and will strengthen the research environment at IUPUI. The proposed research is relevant to the part of NICHD’s mission to insure that that all children have the chance to achieve their full potential free from disease or disability.
Strategies for treatment of Down syndrome: Identifying age- and sex-specific developmental windows using inducible genetic reduction of Dyrk1a
Grant Number
R01AR078663
NIH Institute
NIAMS
Mechanism
R01
The proposed research is relevant to public health because it uses multi-disciplinary innovative approaches to create new scientific paradigms of trisomic gene expression, and establish improved approaches to translate these therapies from preclinical to clinical trials. Inducible genetic approaches in DS mouse models will target the amplified expression of Dyrk1a during critical periods of brain and bone development in trisomic mice, testing the hypothesis that normalization of trisomic gene expression before—but not after—tissue-specific periods of gene dysregulation will correct cognitive and skeletal deficits. The proposed research is relevant to the part of NICHD’s mission to perform research to insure that that all children have the chance to achieve their full potential for healthy and productive lives, free from disease or disability.
Publications
-
Disease models & mechanisms
Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model. -
Genes
Early Chronic Fluoxetine Treatment of Ts65Dn Mice Rescues Synaptic Vesicular Deficits and Prevents Aberrant Proteomic Alterations. -
Bone
Compromised femoral and lumbovertebral bone in the Dp(16)1Yey Down syndrome mouse model. -
Neurobiology of disease
Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model. -
Trends in genetics : TIG
A new Down syndrome rat model races forward. -
Nature communications
Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome. -
Pharmacology, biochemistry, and behavior
Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes. -
PloS one
Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.